OSR Holdings, Inc.
OSRHW
NASDAQ Global Market0.04
USD
+0.00
- -
CIK
0001840425
ISIN
US68840D1101
CUSIP
68840D110
Return %
Stock
S&P500
1Y
2.75
19.01
3Y
37.46
65.48
5Y
37.46
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Kuk Hyoun Hwang
- Full Time Employees
- 22
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10900 NE 4th Street Bellevue WA United States of America 98004
- IPO Date
- Mar 21, 2023
- CIK
- 0001840425
- Website
- osr-holdings.com
- Similar Companies
- Business
- OSR Holdings, Inc. is a global healthcare holding company founded to accelerate healthcare innovation, headquartered in Bellevue, Washington, and publicly listed on NASDAQ since 2025. The company operates a diversified, hub-and-spoke portfolio of subsidiaries specializing in immuno-oncology, regenerative biologics, and medical device technologies. Its core products and services include development of oral T-cell activation therapies targeting tumor vasculature; design-augmented biologics aimed at treating age-related and degenerative diseases, such as DRT-102 for spinal fusion and DRT-101 for osteoarthritis; and the distribution of neurovascular intervention medical devices and noninvasive glucose monitoring systems. OSR Holdings leverages a global network across the United States, Europe, and South Korea to identify and develop transformative healthcare solutions with an emphasis on rigorous science and patient-centered innovation. The company aims to simplify healthcare by centralizing expertise and resources, enabling subsidiary companies to work with agility and focus on high-impact treatments. Its industrial segments encompass biomedical innovation, wellness therapies, and medical systems distribution, serving patient populations worldwide. Recent major developments include OSR Holdings’ strategic roadmap to launch a $50 million security token offering (STO) under Regulation D in the second half of 2025 as part of a blockchain-based capital strategy. This offering complements an $80 million equity line of credit from White Lion GBM Innovation Fund, supporting the company’s goal to build a $100 million reserve in Bitcoin and USDT. Additionally, OSR Holdings continues to pursue partnerships, including term sheet updates with BCM Europe to extend oncology asset licensing, and operational adjustments toward integrating decentralized finance with healthcare innovation. These initiatives reflect significant expansion in the company’s financial and strategic positioning within the biomedical and crypto-healthcare sectors. Overall, OSR Holdings stands as a multi-platform healthcare innovator focused on developing and commercializing novel immunotherapies, biologics, and medical devices while expanding its financial strategies through digital asset integration and global partnerships. It maintains a diversified geographic footprint with operations in the United States, Europe, and Korea, aiming to improve healthcare outcomes and accessibility on a global scale.